Daewoong Pharmaceutical Launches Envlo, Its First Domestic SGLT-2 Inhibitor Medication.
Domestic new drug No. 36 has demonstrated superior blood sugar lowering effects and safety with a low dosage of 0.3mg.
[관련기사 = 대웅제약, 국내 첫 SGLT-2 억제제 신약 '엔블로정' 출시 동시에 보험급여 적용] Daewoong Pharmaceutical has succeeded in localizing a SGLT-2 inhibitor drug for the treatment of diabetes, becoming the first domestic pharmaceutical company to do so. The company announced on May 1 that its new drug, Envlo, has been approved for insurance coverage and will be officially launched in Korea. Envlo is available in a 0.3mg dose (ingredient name: enavogliflozin) and has been approved for three indications: monotherapy, combinati